Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP).

ABSTRACT: MRD2STOP is a pragmatic trial evaluating maintenance therapy cessation guided by measurable residual disease (MRD) negativity in multiple myeloma (MM). Eligible patients had previous MRD < 10^-5, received ≥1 year of maintenance, and were prospectively confirmed to have undetectable disease by positron emission tomography, bone marrow (BM) flow cytometry (limit of detection [LoD] 10^-5), and BM clonoSEQ (LoD 10^-6). BM aspirates enriched for CD138⁺ cells were analyzed by clonoSEQ to achieve MRD 10^-7 sensitivity. We evaluated the incidence of disease resurgence and progression-free survival (PFS), stratified by 10^-7 status. Forty-seven patients discontinued maintenance after a median of

SUBMITTER: Derman BA 

PROVIDER: S-EPMC11458825 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature